Hemostasis diagnostics help identify the hemostatic defects that cause excessive bleeding. Hemostasis is a process of slowing and stopping the blood flow to initiate wound healing after a vascular injury and is the key procedure acting in the first line of action adopted by the body. During the process, blood changes its form from the fluid state to the gelatinous state. Hemostasis is maintained in the body via three mechanisms namely vasoconstriction, platelet plug formation, and blood coagulation. The diagnosis helps predict the cause of excessive bleeding during the surgery, identifies hemostatic defects in patients with a history of excessive bleeding. Based on the research articles published by medical experts, the appropriate therapy to treat hemorrhage can be administered of fresh frozen plasma for coagulation defects, Von Willebrand factor concentrates for platelet function defects or antifibrinolytic agents for systemic fibrinolysis.
Rising prevalence of hemophilia drives the hemostasis diagnostics market globally
The critical nature of the procedure in the field of medicine and healthcare has gained a prominent position in the hemostasis diagnostics market. According to the National Hemophilia Foundation in 2012, the global incidence of hemophilia is estimated to be 400,000 people. The rise in the prevalence of genetically inherited disorders such as hemophilia, an increase in the number of surgeries and trauma patients, the surge in the usage of recombinant products are the collective factors driving the global market.
The growing technological advances in molecular diagnostics, inexpensive and biodegradable diagnostic products, chromogenic substrates, monoclonal antibodies, immunoassays, laboratory automation is estimated to radically change the Hemostasis diagnostics market over the following five years.
North America is the key growth engine in the global hemostasis diagnostics market
Regional segmentation of the Hemostasis Diagnostic Market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. According to the Centre for Disease Control and Prevention in 2015, the number of people with hemophilia in the U.S. is estimated to be 20,000.
This positions North America as the most dominant region in the global hemostasis diagnostics market, owing to the rise in installed instruments leading to higher sales of reagents and support services. According to The European National Registry of Congenital Coagulopathies in 2017, the number of people identified with hemostasis has increased from 7000 in 2000 to over 11,000 in 2015.
Therefore, the European market is expected to grow steadily boosting the demand for hemostasis diagnostics. Significant growth of markets in India, China, and Brazil is registering due to the rise in health care expenditure, higher affordability, improving technical capabilities and economic development. These markets are expected to attract global companies for capitalizing on the hemostasis diagnostics market opportunities.
U.S. Beckman Coulter holds over half the U.S. market for Hematology devices
Key players operating in the market are HORIBA, Ltd., Abbott Laboratories, Siemens AG, and Bio-Rad Laboratories, Inc. The high and low-end analyzers provided by U.S. Beckman Coulter meet the needs of all hematology testing environment. Other vendors who have adopted ideal product models, business expansion and market appeal strategies are Becton, Dickinson & Company, Grifols S.A, Alere, Inc., F. Hoffmann-La Roche AG, Beckman Coulter Inc. Sekisui, Helena Labor, Chrono-Log, and Axis-Shield.
In February 2019, Horiba Medical, launched their new parameter, Yumizen D-Dimer, for its Yumizen G Hemostasis range of instruments to diagnose deep vein thrombosis and pulmonary embolism.
In 2017, Werfen and it's subsidiary Instrumentation Laboratory Company acquired Accriva Diagnostics, to expand leadership in point of care testing.
In 2016, Siemens Healthineers launched Sysmex CS-2500 a new mid-volume coagulation analyzer. Which enable labs to provide quality test results and achieve cost-effective method consolidation.
In 2015, Roche AG launched the new lab-coagulation solution, the cobas t 411 analyzer is lab coagulation system suitable for low volume routine testing (up to 120 samples per day), with this launch Roche AG expanded their diagnostic portfolio.
In 2014, Sysmex Corporation, launched LIASAUTO P-FDP hemostasis reagent for automated coagulation analyzers to determine the status of blood hyperfibrinolysis and hypercoagulable
Hemostasis Diagnostics Market- Taxonomy
The global hemostasis diagnostics market is segmented on the basis of product type, technology, end user and geography.
By Product Type
By Test Type
By End User
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.[email protected]
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.